Plaque reduction neutralization tests (PRNT) were performed to detect the antibody neutralization titers for four serotypes of dengue virus (DENV1 -4) and two strains of Zika virus (ZIKV). The viruses used in current PRNT tests were DENV1 (strain Hawaii), DENV2 (strain 16681), DENV3 (strain H87), and DENV4 (strain H241), and ZIKV (strain MR766 and one recent clinical isolate from an imported subject who was infected in Thailand). The PRNT protocols for DENV and ZIKV were previously described (1,2). Briefly, PRNTs were performed in baby hamster kidney fibroblasts (BHK-21) cells and Vero cells for DENV and ZIKV, respectively. A total of 7 × 10 5 cell per well of BHK-21 cells and Vero cells were seeded in 6-well plates 1 day before PRNT assays. The complement in human serum was inactivated at 56°C
Appendix
*ELISA, enzyme-linked immunosorbent assay; PRNT, plaque reduction neutralization test; ZIKV, Zika virus; DENV, dengue virus; D1, dengue virus serotype 1; D2, dengue virus serotype 2; D3, dengue virus serotype 3; D4, dengue virus serotype 4; Thai, one Zika virus isolate from an imported cases who got infection in Thailand; MR766, the African Zika virus strain MR766. †Six people with positive anti-ZIKV IgM fulfilled the criteria for laboratory confirmation of recent ZIKV infection.
